Fennec Pharmaceuticals Inc. FENC
Institutional shares held
13.9 Million
10K
calls
83.8K
puts
Total value of holdings
$120M
$86K
calls
$720K
puts
Market Cap
$224M
26,067,300
Shares Out.
Institutional ownership
53.47%
# of Institutions
71
We take great care to ensure that the data presented and summarized in this overview for FENNEC PHARMACEUTICALS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FENC
View all-
Southpoint Capital Advisors LP New York, NY4.08MShares$35.1 Million0.72% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$20.7 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.25MShares$19.4 Million9.62% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$10.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA965KShares$8.3 Million0.0% of portfolio
-
Harbert Fund Advisors, Inc. Birmingham, AL467KShares$4.02 Million3.22% of portfolio
-
Aigh Capital Management LLC Baltimore, MD361KShares$3.1 Million1.18% of portfolio
-
State Street Corp Boston, MA338KShares$2.91 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA311KShares$2.68 Million0.0% of portfolio
-
Morgan Stanley New York, NY297KShares$2.55 Million0.0% of portfolio
Latest Institutional Activity in FENC
Top Purchases
Top Sells
About FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Insider Transactions at FENC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 07
2025
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
1,119
-2.0%
|
$8,952
$8.71 P/Share
|
|
Jul 07
2025
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
2,127
+3.66%
|
$4,254
$2.35 P/Share
|
|
Jul 03
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-14.15%
|
$80,000
$8.61 P/Share
|
|
Jun 30
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+1.47%
|
-
|
|
Jun 30
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+6.86%
|
-
|
|
Jun 05
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-13.25%
|
$70,000
$7.78 P/Share
|
|
May 31
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+1.49%
|
-
|
|
May 31
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+6.46%
|
-
|
|
May 22
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,220
+4.93%
|
$41,100
$5.1 P/Share
|
|
May 19
2025
|
Jeffrey S. Hackman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
13,965
+48.21%
|
$83,790
$6.99 P/Share
|
|
May 16
2025
|
Jeffrey S. Hackman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,035
+50.0%
|
$6,210
$6.75 P/Share
|
|
May 16
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
16,667
+9.98%
|
-
|
|
May 16
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
16,667
-19.17%
|
$100,002
$6.78 P/Share
|
|
May 16
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
33,334
+27.72%
|
-
|
|
May 05
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-15.73%
|
$60,000
$6.31 P/Share
|
|
Apr 30
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+3.68%
|
-
|
|
Apr 30
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,042
+0.77%
|
-
|
|
Apr 11
2025
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
1,409
-2.55%
|
$5,636
$4.95 P/Share
|
|
Apr 11
2025
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
2,173
+3.79%
|
$4,346
$2.3 P/Share
|
|
Apr 04
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-14.05%
|
$50,000
$5.25 P/Share
|
Last 12 Months Summary
Buy / Acquisition
182K
Shares
From
6
Insiders
| Exercise of conversion of derivative security | 67.3K shares |
|---|---|
| Open market or private purchase | 15K shares |
| Grant, award, or other acquisition | 100K shares |
Sell / Disposition
205K
Shares
From
3
Insiders
| Open market or private sale | 110K shares |
|---|---|
| Bona fide gift | 95K shares |